In 2018, an elegant paper described, for the first time, that CD39 selectively marked tumor (neoantigen)-specific CD8+TILs, whereas those CD39– comprised bystander CD8+ T cells which are able to recognize a wide range of viral epitopes [23]. Here, ENTPD1 is linked to neoplasm.